A Tearful Tale of Biodesign

Allergan

Michael Ackermann, CEO of a med-tech startup that created a tear-stimulation device for those with dry-eye disease, explains how acquisition by a global pharmaceutical giant is helping him achieve his goal of reaching as many patients as possible. Ackermann, a graduate of the Stanford Byers Center for Biodesign, also discusses why big tech companies have yet to disrupt healthcare and how that translates into big opportunities for entrepreneurs.